Vironova AB - Product Pipeline Review - 2014

Date: June 10, 2014
Pages: 19
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V079E5921C5EN

Download PDF Leaflet

Vironova AB - Product Pipeline Review - 2014
Vironova AB - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Vironova AB - Product Pipeline Review - 2014’, provides an overview of the Vironova AB’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Vironova AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope
  • The report provides brief overview of Vironova AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vironova AB’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vironova AB’s pipeline products
Reasons to buy
  • Evaluate Vironova AB’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vironova AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vironova AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vironova AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vironova AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of Vironova AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Vironova AB SnapshotVironova AB OverviewKey InformationKey FactsVironova AB - Research and Development OverviewKey Therapeutic AreasVironova AB - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyVironova AB - Pipeline Products GlanceVironova AB - Early Stage Pipeline ProductsDiscovery Products/Combination Treatment ModalitiesVironova AB - Drug ProfilesDrug to Inhibit Capsid Protein for HIV-1 InfectionProduct DescriptionMechanism of ActionR&D ProgressSmall Molecule for Influenza A InfectionsProduct DescriptionMechanism of ActionR&D ProgressVN-180Product DescriptionMechanism of ActionR&D ProgressVironova AB - Pipeline AnalysisVironova AB - Pipeline Products by TargetVironova AB - Pipeline Products by Molecule TypeVironova AB - Pipeline Products by Mechanism of ActionVironova AB - Recent Pipeline UpdatesVironova AB - Locations And SubsidiariesHead OfficeOther Locations & SubsidiariesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer


Vironova AB, Key InformationVironova AB, Key FactsVironova AB - Pipeline by Indication, 2014Vironova AB - Pipeline by Stage of Development, 2014Vironova AB - Monotherapy Products in Pipeline, 2014Vironova AB - Discovery, 2014Vironova AB - Pipeline by Target, 2014Vironova AB - Pipeline by Molecule Type, 2014Vironova AB - Pipeline Products by Mechanism of Action, 2014Vironova AB - Recent Pipeline Updates, 2014Vironova AB, Subsidiaries


Vironova AB - Pipeline by Top 10 Indication, 2014
Skip to top

Polycythemia Vera - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 66 pages

Ask Your Question

Vironova AB - Product Pipeline Review - 2014
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: